NCT02838420: A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Hoffmann-La Roche. Phase: PHASE3. Conditions: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer